Overview
| Generic Names: | Allylbarbital; Butalbital M (OH) |
|---|---|
| IUPAC Name: | 5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione |
| Brand Mixtures: | Fiorinal C1/2 Cap (Acetylsalicylic Acid + Butalbital + Caffeine + Codeine Phosphate); Fiorinal C1/4 Cap (Acetylsalicylic Acid + Butalbital + Caffeine + Codeine Phosphate); Fiorinal Tab (Acetylsalicylic Acid + Butalbital + Caffeine); Ratio-Tecnal (Acetylsalicylic Acid + Butalbital + Caffeine); Ratio-Tecnal C 1/2 (Acetylsalicylic Acid + Butalbital + Caffeine + Codeine Phosphate); Ratio-Tecnal C1/4 (Acetylsalicylic Acid + Butalbital + Caffeine + Codeine Phosphate); Trianal Capsules (Acetylsalicylic Acid + Butalbital + Caffeine); Trianal Tablet (Acetylsalicylic Acid + Butalbital + Caffeine); Trianal-C 1/2 Capsule (Acetylsalicylic Acid + Butalbital + Caffeine + Codeine Phosphate) |
| PharmGKB Accession Id: | PA448695 |
Description
Butalbital, 5-allyl-5-isobutylbarbituric acid, is a barbiturate with an intermediate duration of action. It has the same chemical formula as talbutal but a different structure. Butalbital is often combined with other medications, such as acetaminophen or aspirin, and is commonly prescribed for the treatment of pain and headache. [Wikipedia]
Indication
Used in combination with acetaminophen or aspirin and caffeine for its sedative and relaxant effects in the treatment of tension headaches, migraines, and pain.
Pharmacology and Interactions
Mechanism Of Action
Butalbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
Pharmacology
Butalbital is a short to intermediate-acting barbiturate. Barbiturates act as nonselective depressants of the central nervous system (CNS), capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. In sufficiently high therapeutic doses, barbiturates induce anesthesia.
Absorption, Distribution, Metabolism, Elimination & Toxicity
Biotransformation
Hepatic, although most of the dose is eliminated via the kidney (59 to 88%). Urinary excretion products included parent drug (about 3.6% of the dose), 5-isobutyl-5-(2,3-dihydroxypropyl) barbituric acid (about 24% of the dose), 5-allyl-5(3-hydroxy-2-methyl-1-propyl) barbituric acid (about 4.8%).
Protein Binding
45%
Absorption
Well absorbed from the gastrointestinal tract and is expected to distribute to most tissues in the body.
Half Life
35 hours
Toxicity
Symptoms of acute barbiturate poisoning include drowsiness, confusion, coma, respiratory depression, hypotension, and shock.
Chemical Properties
Chemical Formula:
C11H16N2O3
SMILES Code:
CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C
(Format: OpenEye Isomeric)
Molecular Weight ( average / monoisotopic )
224.2563 / 224.1161
Non-Curated Information
A list of non-curated publications that mention this drug along with other genes is available.
Metabolizing Enzymes
Drug Targets
Non-Curated Information
A list of non-curated publications that mention this drug along with other drugs is available.
Non-Curated Information
A list of non-curated publications that mention this drug along with other diseases is available.
LinkOuts
Common Searches
Search PubMed
Search Medline Plus
Search PubChem
Search CTD
Non-Curated Publications
A list of non-curated publications that mention this drug is available.